53 results about "Butyric acid ester" patented technology

The invention provides a polyhydroxyalkanoate composition as well as a preparation method and application thereof. The polyhydroxyalkanoate composition comprises at least two kinds of copolymers of 3-hydroxybutyrate and 4-hydroxybutyrate. The at least two copolymers of 3-hydroxybutyrate and 4-hydroxybutyrate at least comprise one segmented copolymer of 3-hydroxybutyrate and 4-hydroxybutyrate, and in the segmented copolymer, the mass percentage content of a 4-hydroxybutyrate structural unit is 0-20%; the at least two copolymers of the 3-hydroxybutyrate and the 4-hydroxybutyrate at least comprise a random copolymer of the 3-hydroxybutyrate and the 4-hydroxybutyrate. The polyhydroxyalkanoate composition has good strength and toughness, the post-brittleness is also obviously improved, and meanwhile, the polyhydroxyalkanoate composition also has good processability and migration resistance.

An antifungal composition including a first essential oil, and a second essential oil, where the composition is configured to reduce disease onset, pathogen spread, or a combination thereof. Further, an antifungal compound including one or more aroma compounds selected from 4-(4-hydroxyphenyl)-2-butanone, furaneol, ethyl methylphenylglycidate, ethyl hexanoate, ethyl butanoate, beta-ionone, alpha-ionone, (R)-(+)-limonene, (S)-(-)-limonene, cis-3-Hexen-1-ol, nerol, linalool, 2-heptanone, alpha-terpineol, beta-damascenone, β-caryophyllene, ethyl 2-methylbutanoate, β-myrcene, gamma-octalactone, alpha-humulene, nerolidol, (E,E)-2,4-decadienal, (E,E)-α-farnesene, vanillin, phenylethyl acetate, citral, 3-methylbutan-1-ol, or a combination thereof.

The application discloses a non-oxidative weak-acid polyacrylamide degrading agent and a preparation and use method thereof, and the degrading agent comprises the following components: a reducing agent, a regulator, a mutual solvent and water; the reducing agent is one of 3-O-ethyl ascorbic acid ether and L-ascorbic acid-2,6-dibutyrate; the regulator is ammonium chloride; and the mutual solvent is one of ethylene glycol monobutyl ether and isopropyl alcohol. The problems that the existing degrading agent needs to be isolated by a plug for redox reaction with subsequent injected mud acid or secondary precipitation is caused by metal ions such as Na + , K + , Fe 2+ and the like in the degrading agent and subsequent injected mud acid are effectively solved.

The invention discloses a preparation method and application of a bio-based polyester porous membrane, an organic solvent is used as a poly-3-hydroxybutyrate-co-4-hydroxybutyrate solvent, water is used as a non-solvent, and a phase inversion method is adopted to prepare the porous membrane. By adjusting the concentration of the membrane casting solution and the temperature of the coagulating bath, the phase separation behavior in the membrane forming process is regulated and controlled, the poly-3-hydroxybutyrate-co-4-hydroxybutyrate porous membrane with a controllable structure is prepared, and the porous membrane is uniform in pore distribution and high in porosity. The preparation method of the green polymer porous membrane material, provided by the invention, has the advantages of low cost, simple method, easiness in operation, energy conservation, environment friendliness and the like, and has a wide application prospect in the fields of oil-water separation, lithium ion batteries and the like; the problems of non-uniform pore size distribution, poor repeatability and the like of the existing polyhydroxyalkanoate in the phase separation film forming process are solved.

A process for preparing 4-[5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester, in which 1 mole of 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester is reacted with 2.0 to 2.2 moles of chloromethylenedimethyliminium chloride or more than 2.2 to 5 moles of chloromethylenedimethyliminium chloride to prepare a by-product in the form of 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid alkyl ester. The alkyl ester can be hydrolyzed to form 4-[5-[bis(2-chloroethyl)amino]-4-formyl-1-methyl-1H-benzo[d]imidazol-2-yl]butyric acid, which can be used in the pharmaceutical field.

The invention relates to the technical field of compatilizers, and particularly discloses a P34HB-g-GMA compatilizer as well as a preparation method and application thereof. The P34HB-g-GMA compatilizer is prepared from the following preparation raw materials in percentage by mass: 88%-98% of poly (3-hydroxybutyrate-4-hydroxybutyrate), 0.02%-2% of an initiator, 1%-10% of glycidyl methacrylate, 0.1%-1% of an inhibitor, 0.1%-1% of a lubricant and 0.1%-1% of an auxiliary agent, wherein the sum of the mass percentages of the preparation raw materials is 100%. The P34HB-g-GMA, which is prepared by carrying out addition reaction on GMA serving as a grafting monomer and free radicals on a P34HB molecular chain, has the property of a compatilizer, and can be used for effectively improving the compatibility between PHA and other biological materials and improving the stability and the mechanical property of the composite material when being applied to a biodegradable composite material.

The application relates to the technical field of biomaterials, and particularly discloses a PHA combined microsphere as well as a preparation method and application thereof. The PHA combined microsphere provided by the application contains 10-40 wt% of PHA microspheres with a weight average molecular weight of less than 30000 Da and 1-40 wt% of PHA microspheres with a weight average molecular weight of more than 100000 Da, with the PHA being selected from one or more of poly-beta-hydroxybutyric acid, a copolymer of 3-hydroxybutyric acid ester and 3-hydroxyvaleric acid ester, a copolyester of 3-hydroxybutyric acid and 3-hydroxyhexanoic acid and poly(3-hydroxybutyric acid-co-4-hydroxybutyric acid). After the PHA combined microsphere is filled in the skin, on one hand, the PHA combined microsphere can be rapidly degraded in an early stage and promote the reproduction of fibroblasts and endothelial cells in a short time; on the other hand, the PHA combined microsphere can be continuously degraded within 21 weeks and cannot cause inflammation, so that the effect of persistent filling is achieved.

The invention belongs to the technical field of lubricating oil, and particularly relates to a reinforcing agent composition for improving the friction performance of No.8 hydraulic transmission oil and application. The reinforcing agent composition is prepared from the following raw materials: ethyl pyrimiphos, 2-amino-2-oxy-1-(3-phenoxy phenyl) ethyl] 2-(4-dodecylbenzene)-3-methyl butyrate, a dispersing agent and base oil A. The invention further discloses a preparation method of the reinforcing agent composition. According to the invention, a compound system of ethylpyrimidinphosphorus and 2-amino-2-oxy-1-(3-phenoxy phenyl) ethyl] 2-(4-dodecyl-phenyl)-3-methylbutyrate is adopted, so that the friction performance is excellent, the friction performance of the hydraulic transmission oil 8 # can be improved, the test requirements of an Allison C-4 paper-based friction bench are met, and the friction performance of the hydraulic transmission oil 8 # is improved. And the device can adapt to different hydraulic transmission oil formula systems.

The invention discloses a bupivacaine-containing pharmaceutical composition and a preparation method and application thereof.The pharmaceutical composition comprises bupivacaine, sucrose acetate isobutyrate, benzyl alcohol and a stabilizer.The bupivacaine preparation has good stability and a long-acting analgesic effect, the preparation process is simple, and the preparation method is suitable for industrial production. The method is suitable for large-scale production.

A fragrance composition containing a compound represented by Formula (1) as an active ingredient:where in Formula (1), R1 represents a chain hydrocarbon group having from 7 to 20 carbons, and may be linear or branched, and a saturated group or an unsaturated group, and when R1 is an unsaturated group, R1 may have one or more carbon-carbon double bond(s) or carbon-carbon triple bond(s).

The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and / or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to now crystalline forms of cortexolone-17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.

The application provides a preparation method of 4-(hydroxymethyl phosphinyl)-2-oxobutanoic acid, comprising the following steps: a) adding 4-halogen-2-oxobutanoate into dialkyl methyl phosphite dropwise and controlling the temperature to be-30-40 DEG C, and performing a reaction under vacuum to obtain an intermediate liquid; b) mixing the intermediate liquid obtained in the step a) with an acid, performing a hydrolysis reaction, and then performing a purification treatment to obtain 4-(hydroxymethyl phosphinyl)-2-oxobutanoic acid. Compared with the prior art, the preparation method provided by the application uses dialkyl methyl phosphite and 4-halogen-2-oxobutanoate as raw materials, utilizes the SN2 intramolecular rearrangement mechanism, can realize high-efficiency construction of a P-C bond, and the one-step yield of the Arbuzov reaction can be more than 95%, and the final target product 4-(hydroxymethyl phosphinyl)-2-oxobutanoic acid can be obtained through subsequent acidic hydrolysis of the skeleton structure, and the overall yield can be close to 90%; compared with other methods, the preparation method provided by the application is simple in steps, has few reaction by-products, and has a great improvement in yield.

A foodstuff can include a free acid β-hydroxybutyrate, and a base. The β-hydroxybutyrate, and base, are present at a less than 1:1 molar equivalence. Ketone Ester may also be incorporated as a component of the foodstuff.

The application discloses cupriavidus capable of producing polyhydroxyalkanoate by using various carbon sources such as ethanol and application thereof. Cupriavidus The strain sp.ZWJ01 has a preservation number of CGMCC No.37462 in the China General Microbiological Culture Collection Center. The strain can grow and accumulate poly-3-hydroxybutyric acid ester by using various substances such as ethanol, volatile fatty acid and sugar as carbon sources; can grow by using mixed carbon sources of ethanol+propionic acid or ethanol+valeric acid and accumulate poly(3-hydroxybutyric acid-co-3-hydroxyvaleric acid ester) in cells; and can grow by using mixed carbon sources of ethanol+gamma-butyrolactone or ethanol+1,4-butanediol and accumulate poly(3-hydroxybutyric acid-co-4-hydroxybutyric acid) in cells, and has a good application prospect.

Compositions for improving metabolic function in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. S-beta-hydroxybutyrate in pure or enriched form provides energy to the heart, dilates the arteries, decreases blood pressure and systemic vascular resistance, and increases cardiac output. S-Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. S-Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and provide one or more electrolytes. S-Beta-hydroxybutyrate esters provide more controlled release without adding electrolytes. Compositions for improving heart function in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

To provide a perfume composition for deodorization capable of deodorizing all of feces and urine odor, food odor and body odor without generating chemical odor.SOLUTION: The perfume composition for deodorization contains the following components (A) and (B), wherein the mass ratio [(B) / (A)] of the component (B) to the component (A) is 0.12 or more. (A) an aromatic ring-free unsaturated aldehyde having a molecular weight of 100 to 160 and 9 to 10 carbon atoms, and (B) one or more selected from the group consisting of 2-methyl-2-pentenoic acid, cis-3-hexenyl benzoate, citronellyl butyrate, benzaldehyde, trans-3-hexenol, cis-6-none-1-ol, and thymol SELECTED DRAWING: None

Compositions and methods for providing a person with an exogenous and therapeutically effective supply of short chain fatty acids and turmeric extracts (and / or curcuminoids) are disclosed. The compositions include purified butyrate and dried turmeric extracts. The compositions may optionally include purified butyrate and dried turmeric extracts spiked with additional curcumin I, curcumin II, and / or curcumin III. Alternatively, the compositions may include short chain fatty acids (such as butyrate) and purified curcumin I, curcumin II, and / or curcumin III.

The present disclosure relates to biomedical and nutritional uses of highly purified (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate and (R)-3-hydroxybutyrate. In some embodiments, these compounds are employed for enhancing bodily functions and treating various disease states, including cognitive function, muscle power output, inflammation reduction, metabolic disorders, and mitochondrial function. The methods involve combining these ketone esters with natural supplements or medications to improve health outcomes. The disclosure further includes processes for manufacturing and purifying these compounds to ensure high specificity and efficacy in therapeutic applications, providing a comprehensive and enhanced strategy for advancing health and treating diseases.

The present invention provides a compound for use in reducing liver fat in a subject, wherein the compound is selected from:(i) (R)-3-hydroxybutyrate;(ii) an ester of (R)-3-hydroxybutyrate; and(iii) an oligomer obtainable by polymerising (R)-3-hydroxybutyrate moieties;or a pharmaceutically acceptable salt or solvate thereof. The compound is particularly useful in subjects suffering from a fatty liver. The compound can be used to treat non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) or non-alcoholic fatty liver (NAFL).

The invention relates to a fat composition and a nutritional composition comprising such fat composition. The nutritional composition is particularly suitable for therapeutic applications in treating gut discomfort and / or constipation as well as in non-therapeutic applications for reducing the intestinal formation of calcium and magnesium fatty acid soaps. The fat composition comprises a mixture of triacylglycerols (TAG) originating from a bovine milk fat source and a vegetable lipid source, said mixture being characterized by: (a) a content of butanoate groups (C4:0) of 0.5-2.8% by weight based on total weight of fatty acid acyl groups in TAG; (b) a wLCSFA(sn-1,3) of 18.0-35.0% by weight; (c) a mLCFA (sn-1,3) of 48.0-61.0 mol %; and (d) a ratio mLCFA (sn-1,3) / SFA of 0.70-1.25, wherein: —LCFA(sn-1,3) are the long chain fatty acid acyl groups having a chain length of 12 or more carbon atoms at the sn-1 and sn-3 position in TAG; —LCSFA(sn-1,3) are the long chain saturated fatty acid acyl groups having a chain length of 12 or more carbon atoms at the sn-1 and sn-3 position in TAG; —wLCSFA(sn-1,3) is the amount of LCFA(sn-1,3) in % by weight based on total weight of fatty acid acyl groups in TAG; —mLCFA(sn-1,3) is the mole fraction of LCFA(sn-1,3) based on total moles of fatty acid acyl groups in the TAG as expressed in mol %; and—SFA is the mole fraction of saturated fatty acid acyl groups in the TAG as expressed in mol %.

The present invention discloses the prodrugs of hexahydro-β-acid compounds, feed composition and use thereof, and a prodrug of hexahydro-β-acid compound of formula (I), or solvates thereof, or feed-acceptable salts thereof, wherein R1 is selected from a substituted or unsubstituted C1-C2 alkyl, and each of R2 and R3 is independently selected from H and a linear or branched C2-C4 carbonyl, wherein the C2-C4 carbonyl is substituted or unsubstituted. Disclosed herein is that the prodrug of a hexahydro-β-acid compound from esterification by aliphatic acid exhibits excellent stability at high temperature to overcome the problem resulting from the degradation of hexahydro-β-acid compound in a high-temperature pelleting process. Furthermore, disclosed herein is that, both propionate and butyrate, the prodrugs of a hexahydro-β-acid compound from esterification by aliphatic acid, and feed-acceptable salt thereof and solvate thereof, are stable in high-temperature feed processing and achieve effects substantially equal to the hexahydro-β-acid compound in farm breeding.

The application provides a preparation method of glycerol butyrate, comprising the following steps: S1, mixing a lipase solution with a solid phase carrier and oscillating adsorption for 8-24 h; the solid phase carrier comprises at least one of mesoporous silica, macroporous adsorption resin, chitosan microspheres and bacterial cellulose membrane; S2, dispersing the product obtained in S1 in a solution A containing a crosslinking agent, and reacting at a temperature of 4-30 DEG C for 2-12 h to obtain an immobilized lipase; the pH of the solution A is 6.0-8.0; S3, mixing glycerol and butyric acid, then adding the immobilized lipase into the mixture, and reacting at 40-65 DEG C under a vacuum degree of 1-20 kPa for 6-24 h. The method uses the immobilized lipase as a catalyst to catalyze the esterification of food-grade glycerol and butyric acid to synthesize glycerol butyrate in an organic solvent-free system, the reaction condition can be accurately controlled, the product selectivity is high, and the immobilized lipase has high stability and can be efficiently recycled during the reaction process.

The invention provides a polyhydroxyalkanoate composition as well as a preparation method and application thereof. The polyhydroxyalkanoate composition comprises at least two kinds of copolymers of 3-hydroxybutyrate and 4-hydroxybutyrate. The at least two copolymers of 3-hydroxybutyrate and 4-hydroxybutyrate at least comprise one segmented copolymer of 3-hydroxybutyrate and 4-hydroxybutyrate, and in the segmented copolymer, the mass percentage content of a 4-hydroxybutyrate structural unit is 0-20%; the at least two copolymers of the 3-hydroxybutyrate and the 4-hydroxybutyrate at least comprise a random copolymer of the 3-hydroxybutyrate and the 4-hydroxybutyrate. The polyhydroxyalkanoate composition has good strength and toughness, the post-brittleness is also obviously improved, and meanwhile, the polyhydroxyalkanoate composition also has good processability and migration resistance.

The invention discloses a polyhydroxyalkanoate composition and application thereof. The invention relates to a polyhydroxyalkanoate composition. The polyhydroxyalkanoate composition is prepared from the following raw materials: a polyhydroxyalkanoate polymer, polypropylene carbonate-phthalate and a processing aid, wherein the polyhydroxyalkanoate polymer is selected from one or a combination of more of poly (3-hydroxybutyrate), (3-hydroxybutyrate-co-4-hydroxybutyrate) copolymer, (3-hydroxybutyrate-co-3-hydroxyvalerate) copolymer and (3-hydroxybutyrate-co-3-hydroxyhexanoate) copolymer, and the polyhydroxyalkanoate polymer is selected from one or a combination of more of poly (3-hydroxybutyrate), (3-hydroxybutyrate-co-4-hydroxybutyrate) copolymer and (3-hydroxybutyrate-co-3-hydroxyhexanoate) copolymer. The weight percentage of the processing aid in the raw materials is 4-15%, and the processing aid comprises a nucleating agent, a melt flow regulator, an antioxidant, a release agent and an anti-hydrolysis agent. The polyhydroxyalkanoate composition has better processability and is easy to degrade.

A foodstuff can include a free acid β-hydroxybutyrate, and a base. The β-hydroxybutyrate, and base, are present at a less than 1:1 molar equivalence. Ketone Ester may also be incorporated as a component of the foodstuff.

The application discloses an underwater self-repairable high tensile elastomer and a preparation method thereof, and belongs to the field of elastomer preparation. The application aims at solving the problems that the existing self-repairable materials cannot be efficiently self-repaired in a severe underwater environment, cannot maintain the self-repairing efficiency and tensile rate of the materials, and cannot enhance the mechanical properties of the materials. The underwater self-repairable high tensile elastomer is prepared from methyl methacrylate, ethyl acrylate and n-butyl esterified ethyl cellulose. The method comprises the following steps: 1, preparing n-butyl esterified ethyl cellulose; 2, mixing methyl methacrylate and ethyl acrylate; 3, adding the n-butyl esterified ethyl cellulose and dissolving; and 4, ultraviolet curing. The application is used for the underwater self-repairable high tensile elastomer and the preparation thereof.

Provided herein are novel solid forms of each of four compounds: (1) heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate (“Compound 1”), (2) heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (“Compound 2”), (3) heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (“Compound 3”), and (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (“MC3”), and related compositions and methods.

The subject disclosure provides compositions for reducing serum cholesterol and / or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and / or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.